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The distinction between exudates and transudates is very important in the patient management. Here we evaluate whether the
acute-phase protein serum amyloid A (SAA), in comparison with C reactive protein (CRP) and total protein (TP), can be useful in
this discrimination. CRP, SAA, and TP were determined in 36 exudate samples (27 pleural and 9 ascitic) and in 12 transudates (9
pleural and 3 ascitic). CRP, SAA, and TP were measured. SAA present in the exudate corresponded to 10% of the amount found
in serum, that is, the exudate/serum ratio (E/S) was 0.10 ± 0.13. For comparison, the exudate/serum ratio for CRP and TP was
0.39 ± 0.37 and 0.68 ± 0.15, respectively. There was a strong positive correlation between serum and exudate SAA concentration
(r =0.764; p<0.0001). The concentration of SAA in transudates was low and did not overlap with that found in exudates (0.02-
0.21 versus 0.8–360.5g/mL). SAA in pleural and ascitic exudates results mainly from leakage of the serum protein via the inﬂamed
membrane. A comparison of the E/S ratio of SAA and CRP points SAA as a very good marker in discriminating between exudates
and transudates.
Copyright © 2006 Alessandra M. Okino et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Serum amyloid A (SAA) and C-reactive protein (CRP)
are acute-phase proteins predominantly produced and
secreted by hepatocytes [1]. Other cells including lympho-
cytes, monocytes, and macrophages can also produce these
proteins [2]. The induction of SAA and CRP synthesis is
triggered by a number of cytokines, chieﬂy IL-6, which
is released from a variety of cell types, but mainly from
macrophages and monocytes at inﬂammatory sites [3].
Although several studies have investigated the serum
levels of the acute-phase proteins CRP and SAA in diseases
[4–8], few have focused on the levels of these type of proteins
in eﬀusions, that is, transudates and exudates. Serum CRP
is widely used as a marker of inﬂammation and tissue injury
[9, 10]. Although CRP is also found in exudates and it has
been proposed for diﬀerentiating diseases, the diagnostic
application of this ﬁnding has not been fully explored.
For SAA, information regarding its presence and possible
diagnostic use in eﬀusions is not available at all.
Eﬀusions are commonly classiﬁed as transudate or exu-
date according the Light’s criteria that is based in determina-
tions of total protein and lactate dehydrogenase [11]. How-
ever, as the distinction between exudates and transudates are
very important in the patient management, there is a contin-
uous interest in the evaluation of other biochemical param-
eters [12–16]. Plasma ligands of SAA and CRP are distinct
(for review see [17, 18]), supporting that they can diﬀerently
leakage through membranes. The purpose of this study was
to evaluate the presence of SAA in pleural and ascitic ﬂuids,
compare it with CRP, and evaluate the possibility of using
these acute-phase proteins to discriminate eﬀusions.2 Mediators of Inﬂammation
Table 1: Descriptive analysis of parameters determined in serum and exudate samples and their exudate/serum ratio (E/S) (n =36).
Parameters Serum Exudate E/S
Range Mean ±SD Range Mean ±SD Range Mean ±SD
SAA (μg/mL) 20.0–1567.1 307.1 ±341.9 0.8–360.5 33.9 ± 70.5 0.003–0.710 0.10 ±0.13
CRP (μg/mL) 7.3–426.1 130.0 ±109.4 3.0–168.6 40.4 ± 41.6 0.015–2.210 0.39 ±0.37
TP (g/dL) 4.3–9.5 6.3 ±1.3 2.5–8.1 4.3 ± 1.3 0.50–0.98 0.68 ±0.15
Table 2: Descriptive analysis of parameters determined in serum and transudate samples and their transudate/serum ratio (T/S) (n =12).
Parameters Serum Transudate T/S
Range Mean ±SD Range Mean ±SD Range Mean ±SD
SAA (μg/mL) 4.7–47.9 30.5 ±15.9 0.02–0.21 0.1 ±0.04 0.002–0.01 0.004 ±0.003
CRP (μg/mL) 5.4–187.0 84.5 ±54.5 1.5–50.8 13.9 ±13.2 0.01–1.36 0.28 ±0.36
TP (g/dL) 4.3–7.9 5.7 ±0.9 0.3–2.6 1.3 ±0.8 0.08–0.42 0.22 ±0.12
METHODS
SAA,PCR,andtotalprotein(TP)weredeterminedinpleural
andasciticeﬀusionsandcorrespondingserumsamplestaken
from adult patients hospitalized in the Hospital Univer-
sit´ ario/Universidade Estadual de Londrina (Paran´ a, Brazil)
and Hospital Universit´ ario, Universidade de S˜ ao Paulo (S˜ ao
Paulo, Brazil). Pleural and ascitic eﬀusions were classiﬁed as
transudates or exudates according to the Light’s criteria; ef-
fusion to serum total protein ratio >0.5, an eﬀusion lactate
dehydrogenase (LDH) value >200U/L, or a ﬂuid to serum
LDH ratio >0.6 [11]. All of the patients gave their informed
consent to participate in the study, which was approved by
the Ethics Committee of the Hospital Universit´ ario of Uni-
versidade Estadual de Londrina (CEP 111/01) and the Ethics
Committee of the Faculdade de Ciˆ encias Farmacˆ euticas of
Universidade de S˜ ao Paulo (Of´ ıcio CEP no 64).
Serum and exudate samples were taken from 36 hospital-
ized patients, 27 with pleural eﬀusions and 9 with ascitic ef-
fusions. The pleural exudates were caused by pneumonia (18
cases),tuberculosis(7 cases),and neoplasia (2 cases).Theas-
c i t i ce x u d a t e sr e s u l t e df r o mp e ri t o n e a lt u b e r c u l o s i s( 3c a s e s ) ,
peritonitis (1 case), neoplasia (2 cases), cirrhosis (2 cases),
and chronic hepatitis (1 case). Serum and transudate sam-
plesweretakenfrom12patients,9withpleuraleﬀusionsand
3 with ascitic eﬀusions. The pleural transudates were caused
by congestive cardiac failure (5 cases), hepatic cirrhosis (2
cases), and renal failure (2 cases). The ascitic transudates re-
sulted from hepatic cirrhosis (2 cases) and undeﬁned ascite
(1 case).
Thesampleswerecentrifugedat3000rpmfor10minutes
andst or edat−70◦Cforupto10months.CRPwasmeasured
by immunonephelometry, using a Beringher Nephelometer
100 Analyzer and a Dade Behring kit (Marburg, Germany).
SAA was measured by ELISA, using a Tridelta Phase kit
(Maynooth, Co, Kildare). Total protein was measured by a
modiﬁed biuret method in an automated Dimension Clini-
cal Chemistry System analyzer, using the Dade Behring kit.
The Statistical Package for the Social Sciences (SPSS ver-
sion 9.0) program was used to carry out a distribution
analysis by the Kolmogorov-Smirnov test, while the corre-
lation coeﬃcients were determined according to Spearman’s
rank-correlation test and by multiple-level regression analy-
sis. A p value of <0.05 was considered signiﬁcant.
RESULTS
Because the comparative analysis showed no diﬀerences in
the serum and exudate concentrations of SAA, CRP, and TP
with respect to the origin and location of the eﬀusion, a col-
lective descriptive analysis for SAA, CRP, TP, and their ef-
fusion/serum ratio was made for exudates (Table 1)a n df o r
transudates(Table 2). The concentrations of serum and eﬀu-
sion SAA and CRP varied over a broad interval, especially in
exudates.
Likewise, the eﬀusion/serum ratio for CRP and SAA also
varied over a broad interval, specially in exudates (Table 1)
when compared with transudates (Table 2). The exudate dis-
played, on average, 10% and 39% of SAA and CRP present in
the serum, respectively.
The correlation analysis of serum and eﬀusion for SAA,
CRP, and TP (Figure 1) using Spearman’s test showed, in ex-
udates, a stronger correlation for SAA than for CRP and TP
(note the log scale for SAA). Although SAA and CRP were
highly correlated in serum, they were only slightly correlated
in exudate (compare Figures 2(a) and 2(b)).
Albeit the concentration of SAA in transudates was low,
it was possible to identify a correlation between serum and
transudate (see the value of r in Figure 1(a)). Curiously this
correlation was observed only for SAA and was not present
forCRP.TherewasagoodcorrelationbetweenCRPandSAA
inserumbutnotintransudates(Figure 3).TheCRP/SAAra-
tio varied over a broad interval in both exudates and transu-
dates (Table 3).
The analysis of the individual values of SAA, CRP and TP
foundinexudates,transudates,andrespectiveserumshowed
that the simple measurement of SAA in the eﬀusion was able
to discriminate transudate from exudate (Figure 4). This did
not occur with the other parameters.Alessandra M. Okino et al 3
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Figure1:CorrelationbetweeneﬀusionandserumforSAA(a),CRP
(b), and TP (c). Exudates and transudates were from 36 and 12 pa-
tients, respectively. When shown the line represents the regression
for exudates.
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Figure 2: Correlation between CRP and SAA for (a) serum (r =
0.796; p< 0.0001) and (b) exudate (r =0.449; p =0.007) in 36
patients.
DISCUSSION
The concentration of a given plasma protein in an eﬀusion
will depend on its leakage through the pleural and peritoneal
membranes, and for some of them, on local synthesis. Al-
ternatively, proteolysis and cell uptake will contribute to a
decrease in protein concentration (Figure 5). The synthesis
of SAA in the inﬂammatory focus is expected. Indeed, ac-
tivated monocytes express and release SAA [19]. Thus, al-
though local synthesis of SAA can not be excluded, the posi-
tivecorrelationbetweenserumandeﬀusion(Figure 1(a))in-
dicates a strong contribution of serum to the pool of SAA
present in the eﬀusion. The proteolysis of SAA in the exudate
and the association of SAA with cells is expected because: (i)
fragments of SAA are present in synovial ﬂuid of arthritic
patients [20], (ii) SAA undergoes proteolysis by lysosomic
enzymes of neutrophils [21], and (iii) there is a speciﬁc re-
ceptor for SAA in macrophages [22] and neutrophils [23].
These same processes occur with CRP [24, 25]. Based on
the correlations found for CRP and SAA in serum and in4 Mediators of Inﬂammation
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Figure 3: Correlation between CRP and SAA for (a) serum
(r =0.749; p =0.005) and (b) transudate (r =0.247; p =0.438)
in 12 patients.
Table 3: Descriptive values for the CRP/SAA ratio in exudates
(n =36) and transudates (n =12) and respective serum.
CRP/SAA
Range Mean ±SD
Exudate 0.1–31.6 4.7 ±5.8
Serum 0.1–4.2 0.8 ±0.9
Transudate 12.3–423.3 162.6 ±132.7
Serum 0.8–5.0 2.8 ±1.3
exudate (Figure 2), we assume that these proteins cross the
membrane and/or are fragmented to varying degrees, that is,
the passage of CRP through membranes occurs more readily
than the passage of SAA, or the proteolysis or uptake of SAA
by cells is greater than that of CRP.
It is important to note that the concentration of SAA
in exudates is only 10% of that present in serum. However,
this concentration is suﬃciently high to trigger the biological
eﬀects described for this protein, for instance, 1μg/mL of
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Figure 4: Individual values of (a) SAA , (b) CRP, and (c) TP in
serum and eﬀusions (36 exudates and 12 transudates).
SAA is suﬃcient to trigger the mRNA expression and the
release of TNF-α and IL-8 from human neutrophil cultures
[26–28]. Besides the induction of cytokine synthesis and re-
lease[26–29],SAAprimesneutrophils[30]andisinvolvedin
cell migration [31]. CRP binds to phosphocholine and thus
recognize foreign pathogens [32]. Ligand-bound CRP also
activatesthecomplementpathway[33].ThepresenceofCRP
and SAA in exudates supports a key role of these proteins in
the activation of immune responses and/or in the repair of
host tissues.Alessandra M. Okino et al 5
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Figure 5: Factors aﬀecting the concentration of a given protein in an exudate.
The broad range of concentrations for SAA and CRP
in exudates observed in this study was expected and prob-
ably reﬂected diﬀerent phases of the inﬂammatory disease.
Even though, this study suggests the potential value of SAA
in the characterization of exudates, as already proposed for
CRP [9, 34]. Although several molecular markers have been
proposed for the discrimination of exudates and transudates
[35, 36], a deﬁnitive marker has not yet been found. SAA
determinations are relatively simple, rapid, and inexpensive
and in this study we ﬁnd that SAA can undoubtedly con-
tribute to the discrimination of an exudate.
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